Highest-materiality recent filing
American Vanguard enters $285M term loan facility to refinance existing debt
New $225M first lien term loan at SOFR+8.25% (or Base+7.25%) with step-downs; $60M second lien at SOFR+2.00% (3.00% floor).
Net sales $515M vs $547M in 2024; GAAP net loss improved to $50M from $126M.
American Vanguard Q3 net loss narrows, EBITDA improves; reaffirms FY2025 guidance
Q3 net sales $119M flat YoY; gross margin jumped to 29% from 15%.
Maturity extended from Aug 5, 2026 to Dec 31, 2026; borrowing capacity steps down from $245M to $180M by year-end.
American Vanguard Q2 adj EBITDA rises 83% to $11M; reiterates FY guidance
Net sales of $129M (+1% YoY); GAAP EPS $(0.03) vs $(0.42); adjusted EBITDA $11M vs $6M.
American Vanguard regains NYSE compliance; Q1 earnings transcript lacks financial details in filing
NYSE closed April 2 non-compliance notice after company filed Form 10-K and Q1 2025 10-Q.
American Vanguard Q1 net sales $115.8M, EPS ($0.30); Adjusted EBITDA $3.0M down from $15.5M
Net sales of $115.8M, down 14% YoY from $135.1M; GAAP EPS of $(0.30) vs $0.06.
AVD credit amendment extends filing deadlines, reduces revolver by $60M, waives default
FY2024 audited financials deadline extended to 150 days (from 120); Q1 2025 quarterly to 60 days (from 45).
American Vanguard FY2024 adj. EBITDA $42M; guides 2025 revenue $565-$585M
Preliminary Q4 2024 net sales ~$169M vs $172M in Q4 2023; adjusted EBITDA ~$18M vs $22M.
AMVAC Chemical amends credit facility; loosens leverage covenants, restricts dividends and buybacks
Maximum Total Leverage Ratio raised to 6.25x for Q1/Q2 2025, then 5.75x for Q3, returning to 3.25x year-end.
American Vanguard appoints Dak Kaye as CEO effective Dec 9; base salary $650K
Douglas A. ("Dak") Kaye III named CEO effective Dec 9, 2024, succeeding the Office of CEO.
American Vanguard Q3 net sales $118.3M, Adj. EBITDA $1.8M, EPS -$0.92; maintains FY guidance
Net sales $118.3M vs $149.5M YoY; GAAP EPS ($0.92) vs ($0.01).
American Vanguard withdraws Dacthal registrations after EPA suspension based on rodent study
Voluntary cancellation of Dacthal federal registrations submitted to EPA after emergency suspension order on Aug 6, 2024.
American Vanguard Q2 EPS -$0.42; cuts FY2024 EBITDA guidance to $40-50M; EPA suspends Dacthal
Net sales $128.2M vs $132.8M Q2; Adj EBITDA $6.2M vs $10.7M; EPS $(0.42) vs $(0.04).
CEO Eric Wintemute concluded his role effective July 12, 2024; remains Chairman until 2025 annual meeting and will consult part-time.
American Vanguard CEO Eric Wintemute to retire; successor search by Dec 31, 2024
Eric Wintemute to retire as CEO; successor search by Kincannon & Reed.
Net sales $135M (+8% YoY); diluted EPS $0.06 vs $0.07; net income $1.6M vs $1.9M.
AVD reports Q4 net sales $172.2M, EPS $0.25; FY sales $579M; guides 2024 EBITDA $70-80M
Q4 net sales $172.2M (+8% YoY), EPS $0.25 vs $0.13, adjusted EBITDA $21M.
Effective as of July 12, 2024, Eric Wintemute concluded his role as Chief Executive Officer of American Vanguard Corporation (the “Company”).
Mr. Donnelly has also been designated as, and assumed the duties of, the Company’s Acting Chief Executive Officer and acting principal executive officer as of July 12, 2024.
Effective as of July 3, 2024, American Vanguard Corporation (the “Company” or “Registrant”) and Eric Wintemute, the Company’s Chairman and CEO, entered into a Transition Agreement, which set forth the terms and conditions of Mr. Wintemute’s retirement.
On March 7, 2024, American Vanguard Corporation (“Registrant”) issued a press release announcing that Morton D. Erlich had retired from Registrant’s board of directors
Registrant announced its board of directors had appointed Steven Macicek to fill the vacancy to be created by Mr. Erlich’s departure and to commence service on its board effective after the close of business on day upon which Mr. Erlich’s retirement is deemed to be effective (which, in all probability) will be March 15, 2024.
Max materiality 0.85 · Median 0.70 · Most common event earnings